SULFADIAZINE
LOE ApproachingNDAORALTABLET
Approved
Aug 1941
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
SULFADIAZINE by Eli Lilly and Company is clinical pharmacology section silver sulfadiazine has broad antimicrobial activity. First approved in 1941.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sulfadiazine is an oral small-molecule sulfonamide antibiotic with broad-spectrum bactericidal activity against gram-positive and gram-negative bacteria, as well as yeast. It is indicated for toxoplasmosis, HIV infection, burn wounds, radiation dermatitis, and certain cancers. The drug works by inhibiting bacterial cell wall synthesis, with a mechanism distinct from silver nitrate and other antimicrobial agents.
$0.781MPart D
LOE ApproachingDeclining
Product is approaching loss of exclusivity with minimal Part D claims, indicating a shrinking market footprint and likely consolidation of commercial support.
Mechanism of Action
CLINICAL PHARMACOLOGY SECTION Silver sulfadiazine has broad antimicrobial activity. It is bactericidal for many gram-negative and gram-positive bacteria as well as being effective against yeast. Results from in vitro testing are listed below. Sufficient data have been obtained to demonstrate that…
Indications
Worked on SULFADIAZINE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.